by on 11th August 2026
WhatsApp PSP vs a Marketing Blast
Link copied to clipboard!
Many pharma teams in India now use WhatsApp because patients already live there. The risk is treating a promotional blast and a patient support program as the same purchase. They share a channel. They do not share a purpose, a consent model, or a medical review process.
A blast is typically one message, or the same message repeated, sent to a list. That is useful as media: an offer, a campaign film, a reminder about a brand. It is a poor substitute for support after a prescription. The patient has not enrolled through the prescribing doctor, there is no planned next step in week two, and there is no simple way to report a side effect or that they have stopped the medicine.
Delivery numbers can still look healthy, which is why the two get mixed in procurement. Medical affairs will usually not stand behind a thread that reads like advertising. Doctors are reluctant to attach their clinic to it. Patients mute it the way they mute other sales messages. The therapy, meanwhile, is being decided at home with unanswered questions.
What a blast cannot do
A blast has no enrolment identity. You cannot say which doctor this patient came from, or whether they opted in from the room where the medicine was written. “Stop” is an exit, not feedback. There is no library of therapy-specific videos, infographics, or tips for the questions that actually come up in week one—whether to take the dose with food, whether early shedding is expected, whether a rash means they should quit.
None of this makes blasts illegitimate. They are media. The problem starts when they are reported as a patient support program, or when medical is asked to “add content” to a broadcast tool after the vendor has already been signed.
What a support program has to include
A program starts in the clinic. The patient opts in, usually from that doctor’s QR or link, and is tied to that clinic from the first message. After that, WhatsApp has to carry the work of the weeks that follow: medication reminders timed to the regimen, education written for that therapy, and a short way to send feedback so drop-off is not discovered in a quarterly sales slide.
In the programs we run, the centre of that work is the content library—short, doctor-reviewed videos, infographics, and tips for the questions that therapy actually produces—not a generic “take your medicine” ping. The doctor and the MR can see their own slice of enrolment and engagement. Country teams see the roll-up. You can keep the WhatsApp provider you already have; the program sits on top of it.
Comparison: marketing blast vs. patient support program
| Dimension | Marketing blast | Patient support program (PSP) |
|---|---|---|
| Enrolment | Purchased list or unknown opt-in; no doctor attribution | Patient opts in from the prescribing doctor's QR; enrolment auditable per clinic |
| Message sequence | One message (or same message repeated); no therapy-specific path | Structured journey: medication reminders, education, feedback—timed to regimen |
| Content library | Generic or promotional; not therapy-specific | Doctor-reviewed videos, infographics, and tips for that therapy |
| Feedback mechanism | "Stop" to unsubscribe; no structured feedback | Short WhatsApp forms for side effects, confusion, and drop-off |
| Doctor visibility | None—doctor has no view of patient engagement | Doctor dashboard shows their own patients' enrolment and journey status |
| MR / field team visibility | None or manual Excel merge | MR dashboard shows their doctors; country roll-up for brand teams |
| Medical affairs sign-off | Often post-hoc or skipped; content looks like advertising | Copy reviewed and cleared before it goes out |
How to compare the two in a vendor meeting
Three questions usually settle whether you are buying media or a program. Who enrolled this patient, and can you audit that against a doctor? What does the patient receive after the first message—therapy-specific education, or another campaign? Who sees the answers: brand only, or the clinic that wrote the prescription?
Those same questions decide whether a national doctor program holds together in the field. We have written separately about how field teams lose a pharma program when enrolment lives in Excel, and about the patient week itself in how WhatsApp helps adherence.
If you are scoping the next therapy, see how a WhatsApp PSP for pharma is built.